医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

2018年03月09日 PM09:30
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate overview at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium on Friday, March 16, 2018 at 4:30 p.m. local time. The conference will be held March 16-17, 2018 at The InterContinental Hotel Hangzhou.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005084/en/

CONTACT

Investor:
Rx Communications Group
Paula Schwartz,
917-322-2216
pschwartz@rxir.com
or
Media:
SmithSolve
Alex
Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 据国际睡眠专家估计,全球有近10亿人罹患睡眠呼吸暂停
  • 世界中で10億人近くが睡眠時無呼吸症を患っていると世界の睡眠専門家らが推定
  • Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer’s Disease
  • Analytics 4 Life® Expands Its Medical Advisory Board with Global Experts in Cardiology
  • Apogenix Provides Update on Clinical Development of Asunercept